Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

Vanzacaftor-tezacaftor-deutivacaftor (Vnz-Tez-Diva; Alyftrek, Vertex) is indicated for 'the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene'.

The dosage schedule for Vnz-Tez-Diva is available in the summary of product characteristics for:

• Vnz 10 mg, Tez 50 mg and Diva 125 mg tablets

• Vnz 4 mg, Tez 20 mg and Diva 50 mg tablets.

The list price for Vnz-Tez-Diva (excluding VAT; company submission) is £16,110.00 per:

• 84-tablet pack of Vnz 10 mg, Tez 50 mg and Diva 125 mg

• 56-tablet pack of Vnz 4 mg, Tez 20 mg and Diva 50 mg.

The company has a commercial arrangement with NHS England. As part of this agreement, Vnz-Tez-Diva is available to the NHS with a discount. The size of the discount is commercial in confidence.

For information, Vertex did not disclose its Carbon Reduction Plan for UK carbon emissions.